In clinical trials, bepirovirsen showed the potential to address a significant unmet medical need for patients with chronic hepatitis B by reducing hepatitis B surface antigen levels and HBV DNA.
Source link
#FDA #Fast #Tracks #GSK039s #Bepirovirsen #Chronic #Hepatitis #Virus
